| Home | E-Submission | Sitemap | Contact Us
Korean J Med > Volume 86(4); 2014 > Article
The Korean Journal of Medicine 2014;86(4): 425-431.
鍮꾩븣肄붿삱 吏諛⑷컙 吏덊솚쓽 빟臾쇱튂猷
븳由쇰븰援 쓽怨쇰븰 媛뺣궓꽦떖蹂묒썝 냼솕湲곕궡怨
Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
Sang Hoon Park
Division of Gastroenterology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Korea
Corresponding Author: Sang Hoon Park ,Tel: +82-2-829-5121, 5493, Fax: +82-2-846-4669, Email: sanghoon@hallym.or.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Share :  
Weight loss via lifestyle modification remains the most efficient treatment for NAFLD. Weight loss and exercise are the cornerstones of therapy, but achieving long-term lifestyle modification is not free from difficulties. Pharmacologic therapy should be considered for patients with NAFLD unable to achieve or maintain lifestyle-induced weight loss. Unfortunately, there is no approved drug for NAFLD currently. Current treatment methods for NAFLD can be divided roughly into those methods that target components of metabolic syndrome using weight reduction and insulin sensitizers (pioglitazone) and those that use antioxidants (Vitamin E) to benefit the liver. Pioglitazone has been shown to improve steatosis, hepatocellular ballooning, and inflammation and also to reduce the risk of fibrosis progression in several randomized-controlled trials (RCTs). In a large RCT, large doses of vitamin E improved all histological lesions except for fibrosis. Compared with a placebo, Metformin lowered ALT, but did not improve liver histology. Recently, novel anti-diabetic agents (GLP-1 analogues, DPP IV inhibitors) and probiotics that alter the gut microbiome were shown to mildly benefit ALT and liver histology. In this report, we systemically review current pharmacologic therapies and other promising agents that were not considered in the most recent guidelines for the treatment of NAFLD. (Korean J Med 2014;86:425-431)
Keywords: Nonalcoholic fatty liver disease; Pharmacologic therapy; Investigational drugs
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-793-4364, 4311   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community